Business Context and Reporting Period
This Form 8-K is a current report filed by IMMUNIC, INC. on April 1, 2026, covering an event that occurred on March 27, 2026. The filing addresses the company's compliance status with The Nasdaq Stock Market LLC regarding its common stock listing.
Key Financial Metrics
This filing is a non-financial event report (Item 8.01 Other Events). It does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric referenced is the stock price performance required for listing compliance:
- Minimum Bid Price: The company maintained a closing bid price of at least $1.00 per share for 20 consecutive business days (February 27, 2026, to March 26, 2026).
Material Changes
The material change reported is the resolution of a listing deficiency:
- Regained Compliance: Nasdaq determined that Immunic, Inc. has regained compliance with Listing Rule 5550(a)(2) (Minimum Bid Price Requirement).
- Status: The matter regarding the potential delisting or non-compliance is now closed.
Outlook, Risks, and Management Commentary
Management Commentary: The company issued a press release on April 1, 2026, confirming the receipt of the Nasdaq Letter and the restoration of full compliance. No forward-looking guidance, risk factors, or contingencies are disclosed in this specific filing.
Investor Verification Checklist
- Verify the current trading price of IMUX on Nasdaq to ensure it remains above the $1.00 threshold.
- Review the attached press release (Exhibit 99.1) for any additional context on the company's capitalization or market strategy.
- Check subsequent filings for any new compliance notices or financial updates, as this 8-K contains no operational financial data.